CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine. This article examines Medicare coverage for ketamine infusion ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...